ISIS 1 Trial
|
WikiDoc Resources for ISIS 1 Trial |
|
Articles |
|---|
|
Most recent articles on ISIS 1 Trial Most cited articles on ISIS 1 Trial |
|
Media |
|
Powerpoint slides on ISIS 1 Trial |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ISIS 1 Trial at Clinical Trials.gov Clinical Trials on ISIS 1 Trial at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ISIS 1 Trial
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ISIS 1 Trial Discussion groups on ISIS 1 Trial Patient Handouts on ISIS 1 Trial Directions to Hospitals Treating ISIS 1 Trial Risk calculators and risk factors for ISIS 1 Trial
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ISIS 1 Trial |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
In ISIS 1 patients were randomized to treatment with either atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days) or placebo (n=16,027). [1] Atenolol administration was associated with a 15% relative risk reduction in cardiovascular mortality over the first seven days (3.89% versus 4.57%, 2p = 0.04). The combined endpoint of death, cardiac arrest, and reinfarction was also signifcantly reduced (2p < 0.0002). There was a consistent benefit across all subgroups. Following the initial treatment over the first 7 days, the benefit was maintained and slightly fewer events were accrued such at that 1 year, cardiovascular death was significantly lower among patients treated with atenolol (10.7% versus 12.0%, 2p < 0.01).